晚期乳腺癌患者ERCC1、RRM1表达与吉西他滨联合顺铂化疗疗效

THE RELATIONSHIP BETWEEN ERCC1,RRM1 EXPRESSION AND THE EFFECTS OF CISPLATIN COMBINING WITH GEMCITABINE TO TREAT THE PATIENTS WITHMATASTASES BREAST CANCER

目的探讨ERCCl、RRMl在晚期乳腺癌中的表达与吉西他滨联合顺铂化疗疗效关系。方法经病理组织学诊断的IIIb-IV期晚期乳腺癌患者30例,通过免疫组化法检测乳腺癌组织中ERCC1、RRM1的表达水平,预测吉西他滨联合顺铂在晚期乳腺癌中的化疗疗效。结果晚期乳腺癌病理组织中ERCC1阳性率为30.0%(9/30),低表达与高表达化疗后有效率分别为85.7%、33.3%,两组差异有统计学意义(P<0.01);RRM1阳性率为33.3%(10/30),低表达与高表达化疗有效率分别为65.0%、40.0%,两组差异有统计学意义(P<0.01)。结论 ERCC1和RRM1低表达的患者选用吉西他滨联合顺铂方案可提高化疗疗效。提示,ERCC1、RRM1可作为晚期乳腺癌选用吉西他滨联合顺铂方案化疗敏感性的预测指标。

Objective To Explore the relationship between ERCCl,RRMl expression and the effect of gemcitabine combined with cisplatin to treat the matastases breast cancer（MBC）.Methods ERCC1,RRM1 expression levels detection with immunohistochemical assay and the efficacy of gemcitabine combined with cisplatin to treat 30 cases of patients diagnosed as stage IIIb-IV MBC were carried out and evaluated.Results ERCC1 positive rate in MBC was 30.0%（9/30）,The chemotherapy efficacy rate in lowe and high expression of ERCC1 was 85.7% and 33.3%,respectively.the difference was statistically significant（P〈0.01）.The RRM1 positive rate was 33.3%（10/30）,RRM1 low expression and high expression efficiency after chemotherapy was 65.0% and 40.0%,respectively.the difference was statistically significant（P〈0.01）.Conclusion ERCC1,RRM1 expression can be used as a predictor for chemotherapy sensitivity in treatment of MBC.